Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dynamic progression of ectopic lymphoid structure formation in lacrimal glands of a Sjögren's disease murine model.

Frontiers in immunology·2026

Same author

AI-validated fusion proteins for local inhibition of interleukin-17A.

Journal of controlled release : official journal of the Controlled Release Society·2026

Same author

Mitochondrial DNA Variation in the Aging Human Cerebral Cortex and Cerebellum.

Aging cell·2025

Same author

Serum and tear autoantibodies from NOD and NOR mice as potential diagnostic indicators of local and systemic inflammation in Sjögren's disease.

Frontiers in immunology·2025

Same author

Serum and Tear Autoantibodies from NOD and NOR Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren's Disease.

bioRxiv : the preprint server for biology·2024

Same author

Corrigendum to "Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia" [Nanomed: Nanotechnol Biol Med 29C (2020) 102236].

Nanomedicine : nanotechnology, biology, and medicine·2024

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

Imaging and drug delivery using theranostic nanoparticles.

Siti M Janib¹, Ara S Moses¹, J Andrew MacKay¹

¹Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90033-9121, USA.

Advanced Drug Delivery Reviews

|August 17, 2010

Summary

Theranostics combines drug delivery and diagnostics using nanoparticles. This approach targets disease biomarkers for personalized medicine, offering a promising future for integrated therapeutic and diagnostic agents.

More Related Videos

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Experiment Videos

Last Updated: Jun 10, 2026

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Area of Science:

Biomedical Engineering
Nanotechnology
Pharmacology

Background:

Nanoparticle technology is advancing both therapeutic and diagnostic agents.
Theranostics integrates treatment and diagnosis for targeted disease management.
This field is crucial for developing personalized medicine approaches.

Purpose of the Study:

To review state-of-the-art nanoparticles for therapeutic and diagnostic applications.
To discuss the challenges in integrating therapeutic and diagnostic nanoparticle fields.
To highlight the potential of theranostic agents in personalized medicine.

Main Methods:

Review of major nanoparticle classes (e.g., drug conjugates, dendrimers, vesicles, micelles, core-shell particles, microbubbles, carbon nanotubes).
Analysis of contrast agents used for nanoparticle visualization (e.g., optical, metal, ultrasonic, radionuclide).
Discussion of challenges in combining therapeutic and diagnostic functionalities.

Main Results:

Nanoparticles serve as effective carriers for drugs or contrast agents.
Diverse contrast agents enable the observation of nanoparticle-disease interactions.
Integration of therapeutic and diagnostic capabilities is a key focus.

Conclusions:

Theranostics leverages nanoparticles to target disease biomarkers, advancing personalized medicine.
Overcoming integration challenges will accelerate the development of effective theranostic agents.
The potential for rapid treatment assessment and adjustment drives theranostic innovation.